Consistent control of mineral and bone disorder in incident hemodialysis patients

被引:112
作者
Danese, Mark D. [1 ]
Belozeroff, Vasily [2 ]
Smirnakis, Karen [2 ]
Rothman, Kenneth J. [3 ]
机构
[1] Outcomes Insights Inc, Newbury Pk, CA USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] RTI Hlth Solut, Res Triangle Pk, NC USA
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2008年 / 3卷 / 05期
关键词
D O I
10.2215/CJN.01060308
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: In 2003, the National Kidney Foundation introduced guidelines for the control of parathyroid hormone, calcium, and phosphorus in hemodialysis patients. Design, setting, participants, & measurements: A cohort study was conducted of 22,937 incident hemodialysis patients who were identified from a large national provider between July 1, 2000, and June 30, 2002, and followed through June 30, 2004. Consistent achievement was determined (1) as the simultaneous control of multiple markers over time and (2) as the time in target for each marker during the first year of dialysis. Mortality risk was assessed with Cox proportional hazards models. Results: In the simultaneous control analysis, patients who achieved target for none of the markers had a 51% greater risk for death than those who achieved target for all three markers (reference group). Patients who achieved any target for any single marker had a 35 to 39% higher risk for death, and patients who achieved target for any two of the three markers had a 15 to 21% higher risk for death compared with the reference group. In the time in target analysis, patients with parathyroid hormone in target for 4 quarters had a 25% lower risk for death compared with those who did so for :51 quarter (reference group). Patients with calcium in target for 4 quarters had a 14% lower risk, and patients with phosphorus in target for 4 quarters had a 38% lower risk. Conclusions: Consistent control of the markers of bone metabolism and disease within published targets is a strong predictor of survival in hemodialysis patients.
引用
收藏
页码:1423 / 1429
页数:7
相关论文
共 26 条
[1]   Achieving K/DOQI laboratory target values for bone and mineral metabolism:: An uphill battle [J].
Al Aly, Z ;
González, EA ;
Martin, KJ ;
Gellens, ME .
AMERICAN JOURNAL OF NEPHROLOGY, 2004, 24 (04) :422-426
[2]   Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease:: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units [J].
Arenas, M. Dolores ;
Alvarez-Ude, Fernando ;
Gil, M. Teresa ;
Soriano, Antonio ;
Egea, Juan Jose ;
Millan, Isabel ;
Amoedo, M. Luisa ;
Muray, Salome ;
Carreton, M. Antonia .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (06) :1663-1668
[3]  
Arenas MD, 2007, J NEPHROL, V20, P453
[4]   Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation [J].
Avram, MM ;
Mittman, N ;
Myint, MM ;
Fein, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (06) :1351-1357
[5]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[6]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[7]   Impact of the new K/DOQI guidelines [J].
Eknoyan, G ;
Levin, NW .
BLOOD PURIFICATION, 2002, 20 (01) :103-108
[8]  
Gallieni M, 2000, CLIN NEPHROL, V53, P188
[9]  
Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
[10]   Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies [J].
Greenland, S .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 160 (04) :301-305